IGBA welcomes the opportunity to provide comments to the 30 October 2023 proposal for negotiating text of the WHO Pandemic Agreement. As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States in reaffirming the importance of multisectoral collaboration to safeguard human health and build stronger, more resilient health systems.
The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Vinita Gupta, CEO of Lupin, was appointed Chair and Lucas Sigman, CEO of Insud Pharma, Vice-Chair.
- IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care (November 2023)
- IGBA and WHO collaborate on expanding access to quality-assured generic and biosimilar medicines (October 2023)
- IGBA’s CEO Advisory Committee Meets with WIPO Director General Daren Tang (October 2023)
- ANAFAM, the National Association of Medicines Manufacturers of Mexico, joins IGBA (September 2023)
